Regulation of the differentiation and function of osteoclasts

Journal of Pathology

Volumn 192, Issue 1, 2000, Pages 4-13

  Chambers, T J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bone resorption; Macrophage; OPG; Osteoclast; RANKL; TGF ; TNF ; TRANCE

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSFORMING GROWTH FACTOR BETA;

CELL DIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; HUMAN; NONHUMAN; OSTEOCLAST; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

BONE RESORPTION; CARRIER PROTEINS; CELL COMMUNICATION; CELL DIFFERENTIATION; HUMANS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 0033828271     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH645>3.0.CO;2-Q     Document Type: Review

References (127)

1. Trafficking of matrix collagens through bone-resorbing osteoclasts
2. Removal of osteoclast bone resorption products by transcytosis
3. The collagenolytic activity of cathepsin K is unique among mammalian proteinases
4. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice
5. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene
6. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse
7. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
8. Bone and haematopoietic defects in mice lacking c-fos
9. Pleiotropic effects of a null mutation in the c-fos proto-oncogene
10. Osteopetrosis in mice lacking NF-κB1 and NF-κB2
11. The origin of the osteoclast
12. The cellular basis of bone resorption
13. The role of osteoblasts in hormonal control of bone resorption
14. Current concepts review: Cellular biology of bone-resorbing cells
15. Antigens of osteoclasts: Phenotypic definition of a specialized hemopoietic cell lineage
16. The origin of the osteoclast
17. Regulation of osteoclast development and function
18. Osteoblast-like cells in the presence of parathyroid hormone release soluble factor that stimulates osteoclastic bone resorption
19. Partial characterization of a parathyroid hormone-stimulated resorption factor(s) from osteoblast-like cells
20. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
21. The effect of parathyroid hormone and calcitonin on the cytoplasmic spreading of isolated osteoclasts
22. Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts
23. Osteoblasts release osteoclasts from calcitonin-induced quiescence
24. Isolation and characterization of highly enriched, prefusion mouse osteoclastic cells
25. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact
26. Bone cells required for osteoclastic resorption but not for osteoclastic differentiation
27. Osteoclast formation from mononuclear phagocytes: Role of bone-forming cells
28. Generation of osteoclasts in cultures of rabbit bone marrow and spleen cells
29. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse marrow cultures
30. Osteoblastic cells are involved in ostcoclast formation
31. Generation of osteoclasts from hemopoictic cells and a multipotential cell line in vitro
32. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells
33. Enforced expression of Bcl-2 in monocles rescues macrophages and partially reverses osteopetrosis in oplop mice
34. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling
35. Modulation of osteoclast differentiation
36. Parathyroid hormone induces bone resorption in human peripheral blood mononuclear cells
37. Human osteoclast-like cells are formed from peripheral blood mononuclear cells in a co-culture with SaOS-2 cells transfected with the PTH/PTHrP receptor gene
38. Conditionally immortalised murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro
39. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: Studies using VDR knockout mice
40. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
41. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
42. Commitment and differentiation of stem cells to the osteoclast lineage
43. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and identical to TRANCE-RANKL
44. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
45. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
46. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
47. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
48. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
49. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
50. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
51. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
52. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat
53. 3
54. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcaemia of malignancy
55. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
56. Osteoprotegerin (OPG) has potent and sustained antiresorptive activity in postmenopausal women
57. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
58. Interleukin-1β and tumor necrosis factor-α but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
59. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro
60. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures
61. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
62. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function
63. 2, or parathyroid hormone in the microenvironment of bone
64. Characterization of osteoclast precursors in human peripheral blood
65. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
66. TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation
67. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation
68. Localization of RANKL (receptor activator Of NF-κB ligand) mRNA and protein in skeletal and extraskeletal tissues
69. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
70. RANK is the essential signalling receptor for osteoclast differentiation factor in osteoclastogenesis
71. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
72. Expression of functional RANK on mature rat and human osteoclasts
73. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors
74. RANK is essential for osteoclast and lymph node development
75. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signalling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily
76. Receptor activator of NF-κB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase
77. Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase
78. Fra-1 is a transcriptional target of c-Fos during osteoclast differentiation
79. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signalling
80. 2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: Synergistic activation of differentiation, cell spreading, and fusion
81. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells
82. Cellular and hormonal factors influencing monocyte differentiation to osteoclastic bone-resorbing cells
83. Cells of the mononuclear phagocyte series differentiate into osteoclastic lacunar bone resorbing cells
84. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors
85. + dendritic cells
86. + peripheral blood monocytes
87. Differentiation of human dendritic cells from monocytes in vitro
88. Dendritic cells as the terminal stage of monocyte differentiation
89. Heterogeneity of mononuclear phagocytes: An interpretive review
90. Macrophage involvement in wound repair, remodeling, and fibrosis
91. Signal peptide mutations in RANK cause familial expansile osteolysis
92. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor
93. In vivo effects of human recombinant transforming growth factor β on bone turnover in normal mice
94. Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype
95. Inhibition of TGF-β receptor signalling in osteoblasts leads to decreased bone remodelling and increased trabecular bone mass
96. α and β human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria
97. Transforming growth factor beta inhibits resorption in fetal rat long bone cultures
98. Inhibiting and stimulating effects of TGF-β1 on osteoclastic bone resorption in fetal mouse bone organ cultures
99. Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cultures
100. 1 on the regulation of osteoclastic development and function
101. Role of transforming growth factor-beta in bone remodeling
102. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β
103. Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic-stromal cells and inhibits the survival of murine osteoclast-like cells
104. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells
105. Selective induction of Fc gamma RIII on human monocytes by transforming growth factor-beta
106. Deactivation of macrophages by transforming growth factor-β
107. Transforming growth factor-beta primes macrophages to express inflammatory gene products in response to particulate stimuli by an autocrine/paracrine mechanism
108. Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes
109. Other functions, other genes: Alternative activation of antigen-presenting cells
110. Transforming growth factor-beta up-regulates the gene expression of the human platelet-activating factor receptor in monocytic and B cell lines
111. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2 and PAF
112. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
113. Effect of parathyroid extract on blood calcium and osteoclast count in mice
114. Rapid activation of the medullary bone osteoclast cell surface by parathyroid hormone
115. Morphological and ultrastructural aspects of the activation of avian medullary bone osteoclasts by parathyroid hormone
116. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells
117. Tumor necrosis factors α and β induce osteoblastic cells to stimulate osteoclastic bonc resorption
118. Tumor necrosis factor α stimulates osteoclastic differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
119. Functional switching of macrophage responses to tumor necrosis factor-α (TNFα) by interferons
120. Development of functional diversity in mouse macrophages: Mutual exclusion of two phenotypic states
121. Regulation of immune responses by TGF-β
122. Preferential inhibition of cytokine-stimulated bone resorption by recombinant interferon gamma
123. Effects of interleukin 3 and of granulocyte-macrophage and macrophage colony stimulating factors on osteoclast differentiation from mouse hemopoietic tissue
124. Interleukin (IL)-18 (interferon gamma inducing factor) is produced by ostcoblasts and acts via granulocyte macrophage-colony stimulating factor and not via interferon-gamma to ihhibit osteoclast formation
125. Interleukin 4, interferon-γ, and prostaglandin E impact the osteoclast cell-forming potential of murine bone marrow macrophages
126. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages
127. The toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens